NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Ocular Therapeutix, Inc. (OCUL) Stock Analysis

Ocular Therapeutix, Inc. (OCUL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

OCUL

$6.48

−$0.17 (−2.56%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OCUL with… →

OCUL Key Statistics

As of Oct 21, 2026
Trading
Open
$6.69
Previous Close
$6.65
Day's Range
6.38–6.75
52-Week Range
6.00–16.44
Volume
2.49M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.99
Valuation
Market Cap
$1.42B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
27.34
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.40
Financials (FY)
Revenue (FY)
$51.95M−18.47%
Net Income (FY)
−$265.94M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
219.62M
1-Year Return
−44.94%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
3.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OCUL closed at $6.48, −44.94% over 1 year.

Ocular Therapeutix, Inc. (OCUL) has a market capitalization of $1.42B.

In fiscal 2025, OCUL reported revenue of $51.95M.

OCUL Stock Return by Calendar Year

Ocular Therapeutix, Inc. (OCUL) 10-year return: what $10,000 became

1 year
$10,000 $5,506
−44.94%
5 years
$10,000 $5,983
−40.17%
10 years
$10,000 $9,419
−5.81%

If you had invested $10,000 in Ocular Therapeutix, Inc. (OCUL) 10 years ago, at the close on October 21, 2016, it would have been worth $9,419 at the close on October 21, 2026: −5.81% in total, −0.60% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−46.62%
2025+42.15%
2024+91.48%
2023+58.72%
2022−59.68%
2021−66.33%
2020+424.05%
2019−0.75%
2018−10.56%
2017−46.83%
2016 (partial year)+36.99%

As of October 21, 2026.

OCUL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$51.95M−$265.94M−511.9%
2024$63.72M−$193.51M−303.7%
2023$58.44M−$80.74M−138.1%
2022$51.49M−$71.04M−138.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$51.95M$45.38M−$270.02M−$265.94M−511.9%
2024$63.72M$58.10M−$171.78M−$193.51M−303.7%
2023$58.44M$53.16M−$82.38M−$80.74M−138.1%
2022$51.49M$46.95M−$78.65M−$71.04M−138.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OCUL Valuation vs Biotechnology Median

Median of 608 stocks
MetricOCULBiotechnology medianvs median
P/S ratio27.3413.30106% above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Ocular Therapeutix, Inc. (OCUL) at $1.42B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 325.

The 52-week range on file runs from $6.00 to $16.44. The most recent close on file for OCUL is $6.48, dated October 21, 2026. That is −$0.17 (−2.56%) against the previous close. The latest close sits 8% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $51.95M. Against the prior fiscal year total of $63.72M, that is a change of −18.47%. The same year closed with a net loss of $265.94M. Earnings per share on a trailing basis come to −1.4.

Across the 4 fiscal years on file, revenue moves from $51.49M in 2022 to $51.95M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 27.34 times revenue. On price-to-sales that is 105.58% above the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −44.94%. Measured over 10 years, that is −0.60% a year compounded. Beta against the wider market is reported at 0.99. Annualized volatility over the trailing 10 years is 77.36%.

Growth & Income

The record shows no dividend for OCUL.

So far in 2026 the total return is −46.62%. Across the complete calendar years on file, 2020 returned +424.05% and 2021 returned −66.33%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Ocular Therapeutix, Inc. (OCUL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Ocular Therapeutix, Inc. OCUL $1.42B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Ocular Therapeutix, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Visit website →